The TRAIN-HEART consortium, funded by the European Commission (2019-2023), is made up to train a league of 15 promising fellows that harness novel insights in the pathogenesis of ischemic heart failure, study the therapeutic potential of existing RNA therapeutics and improve its efficacy by the design of novel drug delivery systems.


TRAIN-HEART brings together leading academic teams and (biotech) companies covering various disciplines ranging from fundamental research to clinical pharmacology and gene therapy to drug delivery applications, have teamed up in the European Union.

Research Programme

The TRAIN-HEART network aims to gain viable insight in the pathogenesis of ischemic heart failure which will serve as a basis for drug discovery and drug delivery efforts that aim to therapeutically target specific molecules and mechanisms within cardiomyocytes for the treatment of ischemic heart failure.  


If you have any questions you can fill in the form or mail us directly:


Making the most of ‘omics data: Manuel Mayr, King’s College London

Innovative analyses of large and (often) unstructured datasets, ranging from molecular data generated by ‘omics technologies to health data derived from patient records, have the potential to generate important new knowledge that impacts on the prevention, diagnosis, and treatment of cardiovascular disease. Such analyses require a collaborative effort between cardiovascular investigators and specialist data scientists.

This workshop presentation given by Prof. Manuel Mayr, co-hosted by the BHF (the largest independent funder of cardiovascular research in the UK) and the Turing (the UK’s national institute for data science) aims to inspire such cross-disciplinary collaboration by highlighting current opportunities and challenges in the field and by providing a venue for the communities to explore each other’s resources, capabilities and needs.